Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug:152:102987.
doi: 10.1016/j.critrevonc.2020.102987. Epub 2020 May 21.

TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination

Giandomenico Roviello  1 , Sara Fancelli  2 , Marta Rita Gatta Michelet  2 , Giuseppe Aprile  3 , Stefania Nobili  4 , Franco Roviello  5 , Fabio Cianchi  6 , Enrico Mini  4 , Daniele Lavacchi  2
Affiliations
Review

TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination

Giandomenico Roviello et al. Crit Rev Oncol Hematol. 2020 Aug.

Abstract

TAS-102 is a preconstituted drug combination comprising an oral fluoropyrimidine (trifluridine, TFT) and a potent inhibitor of thymidine phosphorylase (tipiracil hydrochloride, TPI). TFT/TPI has recently received Food and Drug Administration (FDA) approval also for the treatment of gastric cancer after at least two lines of chemotherapy. The approval was based on a large phase 3 trial (TAGS), in which TAS-102 showed a 31 % decrease in the risk of death compared with placebo. Here, we review the pharmacological properties, clinical development and potential future directions of TAS-102 in gastric cancer.

Keywords: Chemotherapy; Gastric cancer; TAS-102; Third line.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no conflict of interest.

MeSH terms

LinkOut - more resources